Table 3.
Deterministic cost - effectiveness results of Base Case Lifetime Analysis
| Ivabradine + Standard therapy | Standard therapy | Incremental | |
|---|---|---|---|
| Costs | |||
| Total costs (€) | 8,655 | 5,873 | 2,792 |
| Drug acquisition cost (€) | 5,340 | 2,374 | 2,966 |
| Hospitalization costs (€) | 1,833 | 1,781 | 52 |
| HF management costs (€) | 1,492 | 1,754 | −262 |
| Health outcomes | |||
| QALYs | 4.27 | 3.99 | 0.28 |
| LYs | 5.86 | 5.61 | 0.25 |
| Incremental analysis | |||
| ICER per QALY (€) | 9,986 | ||
| ICER per LY (€) | 11,002 |
ICER: incremental-cost-effectiveness ratio; LY: life-year; QALY: quality-adjusted-life-year.